<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 15.2</label>
 <caption>
  <p>Available treatments for chronic hepatitis B in children</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Treatment</th>
    <th>Licensing</th>
    <th>Dose</th>
    <th>Duration</th>
    <th>Advantages</th>
    <th>Disadvantages</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="3">IFNa</td>
    <td rowspan="3">≥12 months</td>
    <td rowspan="3">5–10 M units/m
     <sup>2</sup> SC 3×/week
    </td>
    <td rowspan="3">6 months</td>
    <td>No resistance</td>
    <td>Side effects</td>
   </tr>
   <tr>
    <td rowspan="2">Usable in young children</td>
    <td>Parenteral administration</td>
   </tr>
   <tr>
    <td>Not for use in decompensated cirrhosis or transplantation</td>
   </tr>
   <tr>
    <td rowspan="3">Lamivudine</td>
    <td rowspan="3">≥3 years</td>
    <td rowspan="3">3 mg/kg po once daily (max 100 mg/day)</td>
    <td rowspan="3">≥1 year</td>
    <td>Few side effects</td>
    <td rowspan="3">High resistance rate</td>
   </tr>
   <tr>
    <td>Usable in young children</td>
   </tr>
   <tr>
    <td>Oral administration</td>
   </tr>
   <tr>
    <td rowspan="2">Adefovir</td>
    <td rowspan="2">≥12 years</td>
    <td rowspan="2">10 mg po once daily</td>
    <td rowspan="2">≥1 year (+6 months after HBeAG seroconversion)</td>
    <td>Partially effective in lamivudine resistant patients</td>
    <td rowspan="2"/>
   </tr>
   <tr>
    <td>Oral administration</td>
   </tr>
   <tr>
    <td rowspan="2">Entecavir</td>
    <td rowspan="2">≥16 years + Phase III (2–17 years)</td>
    <td rowspan="2">0.5 mg/day once Daily (1 mg/day for Lamivudine-resistant pts)</td>
    <td rowspan="2">≥1 year (+6 months after HBeAG seroconversion)</td>
    <td>Partially effective in lamivudine resistant patients</td>
    <td rowspan="2">Not approved for children &lt; 12 years resistant mutations</td>
   </tr>
   <tr>
    <td>Oral administration</td>
   </tr>
   <tr>
    <td rowspan="2">PeglFN</td>
    <td rowspan="2">Phase III (2–18 years)</td>
    <td rowspan="2">180 ug/week</td>
    <td rowspan="2">6 months</td>
    <td>No resistance</td>
    <td>Side effects</td>
   </tr>
   <tr>
    <td>Once weekly administration</td>
    <td>Parenteral administration</td>
   </tr>
   <tr>
    <td rowspan="2">Telbivudine</td>
    <td rowspan="2">Phase 1 (2–18 years)</td>
    <td rowspan="2">600 mg/day once daily</td>
    <td rowspan="2">≥1 year</td>
    <td>Few side effects</td>
    <td rowspan="2">High resistance</td>
   </tr>
   <tr>
    <td>Oral administration</td>
   </tr>
   <tr>
    <td rowspan="4">Tenofovir</td>
    <td rowspan="4">Phase III (12–17 years)</td>
    <td rowspan="4">300 mg/day once daily</td>
    <td rowspan="4">≥1 year</td>
    <td>High response rate</td>
    <td>No available preparation for young children</td>
   </tr>
   <tr>
    <td>No resistance identified</td>
    <td rowspan="3">Reduced mineral density</td>
   </tr>
   <tr>
    <td>Few side effects</td>
   </tr>
   <tr>
    <td>Oral administration</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>Modified from Paganelli et al. [
   <xref ref-type="bibr" rid="CR98">98</xref>]
  </p>
 </table-wrap-foot>
</table-wrap>
